cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Company profile
Ticker
CGEM
Exchange
Website
CEO
Nadim Ahmed
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cullinan Management, Inc., Cullinan Oncology, LLC
SEC CIK
Corporate docs
Subsidiaries
Cullinan Amber Corp. • Cullinan Florentine Corp. • Cullinan Mica Corp. • Cullinan Securities Corp. ...
CGEM stock data
Latest filings (excl ownership)
8-K
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
16 Apr 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
8-K/A
Results of Operations and Financial Condition
8 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
8 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
8 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
10 Aug 23
Latest ownership filings
3
Nate Nguyen
2 Apr 24
4
Corrine Savill
23 Feb 24
4
NADIM AHMED
23 Feb 24
4
Jeffrey Alan Jones
23 Feb 24
4
Jeffrey Trigilio
23 Feb 24
4
Jennifer Michaelson
23 Feb 24
4
JACQUELYN L SUMER
23 Feb 24
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
Jovan-Embiricos Morana
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 64.85 mm | 64.85 mm | 64.85 mm | 64.85 mm | 64.85 mm | 64.85 mm |
Cash burn (monthly) | 25.66 mm | 14.82 mm | 15.08 mm | 14.85 mm | 11.38 mm | 11.76 mm |
Cash used (since last report) | 171.64 mm | 99.11 mm | 100.87 mm | 99.33 mm | 76.12 mm | 78.66 mm |
Cash remaining | -106.80 mm | -34.26 mm | -36.02 mm | -34.48 mm | -11.27 mm | -13.81 mm |
Runway (months of cash) | -4.2 | -2.3 | -2.4 | -2.3 | -1.0 | -1.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 109 |
Opened positions | 13 |
Closed positions | 13 |
Increased positions | 33 |
Reduced positions | 31 |
13F shares | Current |
---|---|
Total value | 342.66 bn |
Total shares | 56.13 mm |
Total puts | 14.20 k |
Total calls | 6.70 k |
Total put/call ratio | 2.1 |
Largest owners | Shares | Value |
---|---|---|
UBS Oncology Impact Fund | 7.91 mm | $234.17 mm |
MPM Oncology Impact Management | 7.65 mm | $69.22 bn |
Biotechnology Value Fund L P | 7.51 mm | $0.00 |
CHI Advisors | 3.41 mm | $30.90 bn |
BVF | 3.20 mm | $28.93 bn |
BEN Franklin Resources | 2.89 mm | $26.16 bn |
BLK Blackrock | 2.24 mm | $20.24 bn |
Braidwell | 1.91 mm | $17.28 bn |
Vanguard | 1.69 mm | $15.28 bn |
Jovan-Embiricos Morana | 1.58 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Feb 24 | Corrine Savill | Common Stock | Sell | Dispose S | No | Yes | 16.18 | 40,000 | 647.20 k | 165,990 |
1 Feb 24 | Corrine Savill | Common Stock | Option exercise | Acquire M | No | No | 4.3 | 40,000 | 172.00 k | 205,990 |
1 Feb 24 | Corrine Savill | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.3 | 40,000 | 172.00 k | 70,331 |
29 Jan 24 | Corrine Savill | Common Stock | Sell | Dispose S | No | Yes | 14.09 | 40,000 | 563.60 k | 165,990 |
29 Jan 24 | Corrine Savill | Common Stock | Option exercise | Acquire M | No | No | 4.3 | 40,000 | 172.00 k | 205,990 |
29 Jan 24 | Corrine Savill | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.3 | 26,003 | 111.81 k | 110,331 |
29 Jan 24 | Corrine Savill | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.3 | 13,997 | 60.19 k | 0 |
23 Jan 24 | Corrine Savill | Common Stock | Sell | Dispose S | No | Yes | 12.46 | 21,316 | 265.60 k | 165,990 |
23 Jan 24 | Corrine Savill | Common Stock | Option exercise | Acquire M | No | No | 4.3 | 21,316 | 91.66 k | 187,306 |
23 Jan 24 | Corrine Savill | Stock Option Common Stock | Option exercise | Dispose M | No | No | 4.3 | 21,316 | 91.66 k | 13,997 |
News
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
17 Apr 24
BTIG Maintains Buy on Cullinan Oncology, Raises Price Target to $30
17 Apr 24
United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday
17 Apr 24
HC Wainwright & Co. Maintains Buy on Cullinan Oncology, Lowers Price Target to $29
17 Apr 24
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Apr 24
Press releases
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
16 Apr 24
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
1 Mar 24